Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

Ionis Pharmaceuticals (IONS) reported a loss of 6 cents per share for fourth-quarter 2023, which was significantly narrower than the Zacks Consensus Estimate of a loss of 78 cents per share.The bottom line includes compensation expenses related to equity awards. Excluding these special items, adjusted earnings per share were 12 cents against a loss of $1.18 per share in the year-ago quarter.Total revenues were $325 million in the fourth quarter, which beat the Zacks Consensus Estimate of $184.0 million. Rev ...